Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
321 results about "Steatosis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Steatosis, also called fatty change, is the process describing the abnormal retention of lipids within a cell or organ. When not further specified (such as cardiac steatosis), it is defined as affecting the liver. It reflects an impairment of the normal processes of synthesis and elimination of triglyceride fat. Excess lipid accumulates in vesicles that displace the cytoplasm. When the vesicles are large enough to distort the nucleus, the condition is known as macrovesicular steatosis; otherwise, the condition is known as microvesicular steatosis. While not particularly detrimental to the cell in mild cases, large accumulations can disrupt cell constituents, and in severe cases the cell may even burst.
Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
A pharmaceutical combination comprising an effective amount of at least one cholesterol absorption inhibitor and at least one microsomal triglyceride transfer protein inhibitor (MTP).
Owner:SCHERING CORP
Thyromimetics for the Treatment of Fatty Liver Diseases
InactiveUS20090232879A1Low in fatPreventing and treating and ameliorating fatty liver diseaseBiocideMetabolism disorderSteatosisReceptor
The present invention is directed toward the use of thyromimetic compounds that are thyroid receptor ligands, pharmaceutically acceptable salts thereof, and to prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.
Owner:METABASIS THERAPEUTICS INC
Therapeutic agents for adiposity or fatty liver
The invention relates to a medicine with icaritin as active component for treating obesity or fatty livers. The pharmacological experiment shows that the icaritin is an effective fatty acid synthetase inhibitor; can inhibit food intake and reduce weight of DIO mice; reduce adipose degeneration of the livers; and reduce the degree of ischemia / reperfusion injuries of the livers with adipose degeneration. The acute toxicity test of the icaritin on the mice shows that the icaritin has no toxicity. Therefore, the icaritin has wide development prospect, and can be used for preparing new drugs for treating obesity or fatty liver.
Owner:殷正丰 +2
Animal model for HCV infection
The present invention relates to a non-transgenic, non-human animal useful as a model for protease activity and for liver damage, including steatosis.
Owner:VERTEX PHARMA INC
Cyanotriazole compounds
ActiveUS20160229816A1Stimulates citric acid cycle activityImproving hyperglycemiaOrganic active ingredientsMetabolism disorderDyslipidemiaSide effect
This invention relates to a cyanotriazole compound represented by the formula (1):wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and / or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and / or preventing diseases or disorders on which citric acid cycle activation and / or improvement of hyperglycemia has a prophylactic and / or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and / or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.
Owner:OTSUKA PHARM CO LTD
Compositions and methods for ameliorating hyperlipidemia
InactiveUS20090042835A1Reduce decreaseReducing hepatic lipid secretionBiocideMetabolism disorderSide effectMicrosomal triglyceride transfer protein
The invention provides compositions comprising a pharmaceutical compound having one or more Microsomal Triglyceride Transfer Protein (MTP) inhibitors that are covalently linked to one or more Liver Fatty Acid-Binding Protein (L-FABP) inhibitors. Also disclosed are methods for using the inventive pharmaceutical compositions in the treatment of hepatic steatosis and hyperlipidemia while avoiding the harmful side effects of steatorrhea.
Owner:DAVIS ROGER A
Compositions and methods for the reduction or prevention of hepatic steatosis
ActiveUS20160067201A1Lower Level RequirementsReduction of non-alcoholic steatohepatitis (NASH)BiocidePeptide/protein ingredientsSteatosisMetabolite
Methods useful for reducing or preventing non-alcoholic steatohepatitis or hepatic steatosis are provided herein. Such methods may comprise administering to a subject in need thereof a sirtuin pathway activator and / or PDE5 inhibitor alone or in combination with an amount of a branched amino acid in free amino acid form, or a metabolite thereof. Also provided herein are compositions and kits for practicing any of the methods described herein.
Owner:NUSIRT SCI
Non-invasive assessment of liver fat by crawling wave dispersion with emphasis on attenuation
InactiveUS20140316267A1Inexpensive and easy-to-useSimultaneous measurementOrgan movement/changes detectionInfrasonic diagnosticsSteatosisUltrasound attenuation
Using a modified ultrasound device, crawling waves are applied to the liver over a range of shear wave frequencies. Dispersion measurements are obtained that reflect tissue viscosity and these correlate with the degree of steatosis. A device for the process has an actuator on either side of the ultrasound transducer to apply shear waves, which interfere to produce the crawling waves.
Owner:UNIVERSITY OF ROCHESTER
Bifidobacterium cect 7765 and use thereof in the prevention and/or treatment of excess weight, obesity and related pathologies
InactiveCN103619343AReduce volumeReduce accumulationAntibacterial agentsBacteriaDyslipidemiaCellular component
The invention relates to Bifidobacterium CECT 7765 and to the use thereof in the prevention and / or treatment of overweight, obesity and related pathologies. The invention likewise relates to the Bifidobacterium CECT7765 strain, to the cellular components, metabolites and secreted molecules thereof, to the combinations thereof with other microorganisms, and to compositions that include the preceding products, as well as to the use of one strain of the species Bifidobacterium pseudocatenulatumo and to the use of the CECT 7765 strain for preventing and / or treating obesity; excess weight; hyperglycemia; and diabetes, preferably type-2 Diabetes Mellitus; hepatic steatosis or fatty liver; dyslipidemia; metabolic syndrome; immune system dysfunction associated with obesity and excess weight; and an imbalance in the composition of the intestinal microbiota associated with obesity and excess weight.
Owner:CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Bifidobacterium cect 7765 and use thereof in the prevention and/or treatment of overweight, obesity and associated pathologies
InactiveUS20140369965A1Prevention and treatment of overweightSmall sizeAntibacterial agentsBiocideAcute hyperglycaemiaDyslipidemia
The present invention relates to the Bifidobacterium CECT 7765 strain, to its cell components, metabolites, and secreted molecules, to the combinations thereof with other microorganisms, and to compositions comprising the aforementioned products, as well as to the use of a strain of the Bifidobacterium pseudocatenulatum species, or to using the CECT 7765 strain for the prevention and / or treatment of obesity, overweight, hyperglycemia and diabetes, preferably type 2 diabetes mellitus, hepatic steatosis or fatty liver, dyslipidemia, metabolic syndrome, immune system dysfunction associated with obesity and overweight; and an unbalanced composition of the intestinal microbiota associated with obesity and overweight.
Owner:CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
ActiveUS20190255084A1Increased riskPrecise definitionPeptide/protein ingredientsDigestive systemHepatitis c viralLiver steatosis
Owner:APHAIA PHARMA AG +1
Diagnosis method of hepatic steatosis using biochemical markers
ActiveUS20060173629A1Low costReduce riskData processing applicationsMicrobiological testing/measurementLiver fibrosisBiochemical markers
The present invention is drawn to a new diagnosis method for detecting the extent of hepatic steatosis in a patient, in particular in a patient who suffers from a disease involving hepatic steatosis, or who already had a positive diagnosis test of liver fibrosis and / or presence of liver necroinflammatory lesions, by using the serum concentration of easily detectable biological markers. The invention is also drawn to diagnosis kits for the implementation of the method.
Owner:ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
Novel methods for assessing the level of triglycerides in the liver of a subject are described, comprising determining the amount of a lipid metabolite in a sample from a body fluid of the subject. The methods may be used, for example, in diagnosing and monitoring liver disorders such as steatosis, NAFLD and NASH.
Owner:METABOLON
Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis C virus infection
ActiveUS9370528B2Reduce the possibilityIncrease opportunitiesBiocidePeptide/protein ingredientsHepatocellular carcinomaInsulin resistance
The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and / or prevention of an array of the manifestations of metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including Hepatitis B and Hepatitis C viral infections, as well as the secondary disease states and / or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions.
Owner:SAPIENZA RES LLC +1
Compositions and methods for ameliorating hyperlipidemia
InactiveUS20080241869A1Decreased plasma lipidReduce hyperlipidemiaOrganic active ingredientsMetabolism disorderSteatosisSecondary hyperlipidemia
The invention provides compositions and methods for treating hyperlipidemia by administering a Microsomal Triglyceride Transfer Protein (MTP) inhibitor in combination with a Liver Fatty Acid-Binding Protein (L-FABP) inhibitor, methods of preventing the development of hepatic steatosis, methods of identifying an agent useful for treating hyperlipidemia, and methods of screening for inhibitors of MTP and L-FABP activity. Also provided are pharmaceutical compositions comprising a MTP inhibitor and a L-FABP inhibitor.
Owner:SAN DIEGO STATE UNIV RES FOUND
Synergistic bifunctional protein for regulating blood sugar and lipid
The invention relates to a synergistic bifunctional protein for regulating blood sugar and lipid. The synergistic bifunctional protein comprises a human GLP-1 analog and human FGF21. In one aspect, the invention provides a method for preparing the synergistic bifunctional protein, and on the other hand, the invention also provides an application of the synergistic bifunctional protein for treatment of type 2 diabetes, obesity, dyslipidemia, fatty liver disease and / or metabolism syndrome drugs. The synergistic bifunctional protein provided by the invention can synergistically regulate blood sugar and lipid levels in vivo, and meet the multiple needs of hypoglycemia, alleviation of liver fatty degeneration, weight reduction and improvement of circulating lipid metabolism disorder in type 2 diabetic patients.
Owner:AMPSOURCE BIOPHARMA (SHANGHAI) INC
Compounds and compositions comprising such compounds for the prevention or treatment of dyslipidaemias
ActiveUS20160256429A1Reduce Toxicity RiskImprove the situationOrganic active ingredientsMetabolism disorderDyslipidemiaSterol
The present invention relates to the field of medicine. It more particularly relates to the use of compounds for preventing and / or treating dyslipidemia in a subject, said dyslipidemia typically being linked to the excess presence in the biological membranes, including in the biological membranes of non-adipocyte cells, of fatty acids, in particular of saturated long-chain fatty acids, and / or of sterols. The invention also relates to compositions, in particular pharmaceutical compositions and food supplements or complements, comprising such compounds, and to the uses thereof for preventing and / or treating dyslipidemia. The compounds and compositions according to the invention can in particular be advantageously used for preventing and / or treating a pathological condition selected from metabolic syndrome and / or a symptom or abnormality characteristic of metabolic syndrome, preferably for preventing or treating type 2 diabetes mellitus or hepatic steatosis.
Owner:CENT NAT DE LA RECHERCHE SCI +2
Aromatic-ring azacyclo derivatives and application thereof
InactiveCN105777632AHigh expressionOrganic chemistryMetabolism disorderAcute hyperglycaemiaSteatosis
Aromatic-ring azacyclo derivatives and an application thereof are provided. The invention relates to compounds represented by the formula (V), and a preparation method and an application thereof in medicines. In particular, the invention relates to derivatives of the compounds represented by the general formula (V), and a preparation method and the application thereof as therapeutic agents in prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, type-II diabetes, hyperglycemia, obesity or insulin resistance syndromes and metabolic syndromes. The compounds disclosed by the invention also can reduce total cholesterol, LDL-cholesterol and triglycerides, increase the expression of hepatic LDL receptors and inhibit the expression of PCSK9.
Owner:CHENGDU BESTCHIRALBIO LIMITED LIABILITY
Prevention and treatment of inflammatory conditions
ActiveUS20140187504A1Rapid recruitmentSuppresses in vitro proliferationBiocidePeptide/protein ingredientsAlcoholic cirrhosisTazarotene
The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ALD). More specifically the present embodiments relate to the prevention and treatment of ALD through the administration of an Retinoic Acid Receptor (RAR) agonist. Some embodiments relate to use of tazarotene in the prevention and treatment of alcohol-induced liver injury, alcohol-related liver disease, fatty liver disease, hepatic steatosis, alcoholic hepatitis or alcoholic cirrhosis.
Owner:GRI BIO INC
Pharmaceutical use of Graptopetalum and related plants
ActiveUS7364758B2No detectable side effectImprove survival rateBiocideAntipyreticDiseaseLiver fibrosis
Owner:TAICHUNG VETERANS GENERAL HOSPITAL +1
Composition with auxiliary protection effect on alcoholic liver injury and preparation method thereof
InactiveCN104172159ASuitable for useScientific and reasonable formula designOrganic active ingredientsDigestive systemSalvia miltiorrhizaSemen
The invention discloses a composition with an auxiliary protection effect on an alcoholic liver injury and a preparation method of the composition. The composition with the auxiliary protective effect on the alcoholic liver injury is mainly prepared from the following raw materials in parts by weight: 57.5-172.5 parts of kudzuvine root extract, 22.5-67.5 parts of semen hoveniae extract, 35-105 parts of salvia miltiorrhiza extract, 18-57 parts of turmeric extract and 7.5-22.5 parts of ammonium glycyrrhetate. The raw materials respectively have anti-lipid peroxidation effect and protective effect on the liver. Functional tests show that the composition with the auxiliary protection effect on the alcoholic liver injury has better liver protection effect compared with the same dose of single kudzuvine root extract preparation and single semen hoveniae extract preparation, and liver fatty degeneration and liver lipid peroxidation which are caused by the alcoholic liver injury can be obviously alleviated. The composition with the auxiliary protection effect is prepared by adopting a scientific and reasonable production process, is definite in functions, controllable in quality and safe to take and is applicable to a large group of people suffering from the alcoholic liver injury.
Owner:BEIJING ZHONGTAI TIANHE SCI & TECH
Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection
ActiveUS20130337055A1Reduce the possibilityIncrease opportunitiesBiocidePeptide/protein ingredientsHepatocellular carcinomaInsulin resistance
The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and / or prevention of an array of the manifestations of metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including Hepatitis B and Hepatitis C viral infections, as well as the secondary disease states and / or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions.
Owner:SAPIENZA RES LLC +1
Pharmaceutical use of water-soluble fraction of Graptopetalum
ActiveUS7588776B2No detectable side effectInhibit inflammationBiocideDigestive systemSteatosisDisease
A pharmaceutical composition containing a water-soluble fraction of Graptopetalum and its use in treating a liver disease or condition, such as inflammation, steatosis, and fibrosis.
Owner:TAICHUNG VETERANS GENERAL HOSPITAL +1
Use of leptin for the treatment of fatty liver diseases and conditions
ActiveUS20110212889A1Liver inflammation is reducedDecrease triglyceride accumulationHormone peptidesPeptide/protein ingredientsSteatosisLeptin Deficiency
The invention generally relates to the use of leptin in the treatment of a leptin-responsive disease or condition in a non-lipodystrophic subject. More particularly, the invention is directed to the use of leptin in the treatment of a fatty liver disease in a non-lipodystrophic subject with a relative leptin deficiency. The invention includes methods for the treatment of nonalcoholic steatohepatitis (NASH), alcoholic fatty liver disease (AFLD), and nonalcoholic fatty liver disease (NAFLD) in a non-lipodystrophic subject. The invention includes the treatment of conditions ranging from ectopic lipid accumulation (steatosis) to cirrhosis.
Owner:RGT UNIV OF MICHIGAN
Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
Owner:ENANTA PHARM INC
A novel composition for nonalcoholic fatty liver disease (NAFLD)
Owner:CADILA HEALTHCARE LTD
Traditional chinese medicine composition for sober-up and hepatic protection and a process for preparing the same
ActiveUS20160310554A1Effectively soberRelieve drunkenness symptomsPowder deliveryDispersion deliverySteatosisAlcohol
The present invention relates to traditional Chinese medicine, particularly to a traditional Chinese medicine composition for sober-up and hepatic protection and a process for preparing the same. This composition is made from Radix Puerariae, Semen Hoveniae and Fructus Gardeniae. This composition has no significant effect on the body weight of mice. The hepatic TG level in animals of 1.400 g / kg·bw dosage group is significantly lower than that of the model control group, while the hepatic GSH level is significantly higher than that of the model control group. The degree of hepatic steatosis in animals of 1.400 g / kg·bw dosage group is significantly lower than that of the model control group. Therefore, the composition of the present invention has auxiliary protective effects on liver damages caused by alcohol. The process for preparing the composition comprises: extracting Radix Puerariae, Semen Hoveniae and Fructus Gardeniae with water, concentrating, drying, and pulverizing the extract.
Owner:INFINITUS (CHINA) CO LTD
Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof:which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
Owner:ENANTA PHARM INC
Tetrahydrocoptisine derivative and applications thereof
InactiveCN105418601AMetabolism disorderGroup 5/15 element organic compoundsLiver steatosisPancreatic hormone
The present invention relates to a compound as shown in a formula (VII), a preparation method and applications thereof in medicines. In particular, the present invention relates to a derivative of the compound as shown in the formula (VII), a preparation method, and the applications of the derivative used as a therapeutic agent in prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, II-type diabetes, hyperglycemia, obesity or insulin resistance syndrome and metabolic syndrome. The compound disclosed by the present invention can also reduce total cholesterol, LDL-cholesterol and triglyceride, and increases expression of a liver LDL receptor and decreases expression of PCSK9.
Owner:CHENGDU BESTCHIRALBIO LIMITED LIABILITY
Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
Owner:ENANTA PHARM INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com